INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference
March 14 2022 - 4:30PM
INmune Bio (NASDAQ: INMB), a clinical stage immunology company
focused on developing treatments that harness the patient’s immune
system to fight disease, announced today that RJ Tesi, MD.,
President and CEO has been invited to participate in the 32nd
Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group
Virtual Growth Conference.
Dr Tesi will present a corporate overview at the 32nd Annual
Oppenheimer Healthcare Conference, which is being held virtually on
March 15 – 17, 2022.
Event Details
Date: Wednesday, March
16, 2022
Time: 11:20am ET
To set up 1X1 meetings with management, please contact your
Oppenheimer representative.
Dr. Tesi will participate in a fireside chat with Jason
McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology
Research at Maxim Group during the 2022 Maxim Group Virtual Growth
Conference, which is being held virtually on March 28 – 30,
2022.
Event Details
Date: Wednesday, March
30, 2022
Time: 11:00am ET
Register:
https://m-vest.com/events/2022-virtual-growth-conference.
About INmune Bio, Inc.
INmune Bio, Inc.
is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology
company focused on developing treatments that target the innate
immune system to fight disease. INmune Bio has two product
platforms that are both in clinical trials. The DN-TNF product
platform utilizes dominant-negative technology to selectively
neutralize soluble TNF, a key driver of innate immune dysfunction
and mechanistic target of many diseases. DN-TNF is in clinical
trial to determine if it can treat cancer (INB03™), Mild
Alzheimer’s disease, Mild Cognitive Impairment and treatment
resistant depression (XProTM). The Natural Killer Cell Priming
Platform includes INKmune™ aimed at priming the patient’s NK cells
to eliminate minimal residual disease in patients with cancer.
INmune Bio’s product platforms utilize a precision medicine
approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation. To learn more,
please visit www.inmunebio.com.
Information about Forward-Looking
Statements
Clinical trials are in early stages and there is no assurance
that any specific outcome will be achieved. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XProTM, and INKmune™ are
still in clinical trials or preparing to start clinical trials and
have not been approved and there cannot be any assurance that they
will be approved or that any specific results will be achieved. The
factors that could cause actual future results to differ materially
from current expectations include, but are not limited to, risks
and uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact: David Moss, CFO
DMoss@INmuneBio.com(858) 964-3720
Investor Contact: Core IR Jason Nelson
info@inmunebio.com516.842.9614 x-823.
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jul 2024 to Aug 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Aug 2023 to Aug 2024